Adrenoleukodystrophy: An Overview of a Rare Genetic Disorder
Published: 2022-10-10
Page: 140-150
Issue: 2022 - Volume 5 [Issue 1]
Adedeji Okikiade *
All Saints University, College of Medicine, Saints Vincent and the Grenadines.
Damisola Ogunesan
Lagos University Teaching Hospital, IDI -ARABA, Lagos, Nigeria.
Franklyn Ndu
All Saints University, College of Medicine, Saints Vincent and the Grenadines.
Jeffery Ndu
All Saints University, College of Medicine, Saints Vincent and the Grenadines.
Peace Njoku
All Saints University, College of Medicine, Saints Vincent and the Grenadines.
Katlego Ramaphane
All Saints University, College of Medicine, Saints Vincent and the Grenadines.
*Author to whom correspondence should be addressed.
Abstract
Adrenoleukodystrophy (ALD) is caused by an X-linked inborn error of metabolic disorder due to the mutation of ATP binding cassette subfamily D member 1 (ABDC 1) gene. Three types of ALD cerebral form affect children aged 5-10, while the adrenomyeloneuropathy (AMN) form affects middle-aged men. The latter usually causes adrenal insufficiency, more commonly seen in men. This condition usually presents vast signs and symptoms based on the type one has and gender. Diagnosis of ALD is based on clinical manifestations and laboratory investigations which include measurement of very long chain fatty Acids (VLCFAs) blood levels and abnormal Magnetic resonant image (MRI) findings of white matter, pyramidal tracts in the brain stem, and internal capsules.
Stem cell transplants using hemopoietic stem cells and ex-vivo gene treatment have been used to slow disease progression without a traditional treatment regimen. This review article is partly a teaching session for medical students and other health practitioners, fostering their research skills and integrative learning.
Keywords: Adrenoleukodystrophy, leukodystrophy, ABCD1 gene, VLCFA, genetic disorder, adrenal insufficiency
How to Cite
Downloads
References
Turk BR, Theda C, Fatemi A, Moser AB. X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies. Int J Dev Neurosci. 2020;80(1):52-72.
DOI: 10.1002/jdn.10003. Epub 2020 Jan 26. PMID: 31909500; PMCID: PMC7041623
Ali Fatemi MD. Department of Neurogenetics, Kennedy Krieger Institute , NORD Rare Disease Database X-Linked Adrenoleukodystrophy: signs & symptoms and causes; 2021.
Mahdi Alsaleem, Lina Saadeh. Adrenoleukodystrophy: Introduction, etiology, histopathology; 2021.
Available:https://www.ncbi.nlm.nih.gov/books/NBK562328/
Cleveland Clinic. ALD(Adrenoleukodystrophy)- symptoms and causes, diagnosis and tests, management and treatment, prevention and outlook/prognosis; 2021.
Berger J, Forss-Petter S, Eichler FS. Pathophysiology of X-linked adrenoleukodystrophy. Biochimie [Internet]. 2014;98:135–42.
Available:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988840/
Mayo Clinic Adrenoleukodystrophy - Symptoms and causes [Internet, 2018].
Available:https://www.mayoclinic.org/diseases-conditions/adrenoleukodystrophy/symptoms-causes/syc-20369157
Alsaleem M, Saadeh L. Adrenoleukodystrophy [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2022.
Available:https://www.ncbi.nlm.nih.gov/books/NBK562328/
Dong B, Lv W, Xu L, Zhao Y, Sun X, Wang Z, et al. Identification of Two Novel Mutations of ABCD1 Gene in Pedigrees with X-Linked Adrenoleukodystrophy and Review of the Literature. International Journal of Endocrinology [Internet]. 2022;e5479781.
[Cited 2022 Apr 26]
Available:https://www.hindawi.com/journals/ije/2022/5479781/
Turk BR, Theda C, Fatemi A, Moser AB. X‐linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening, and therapies. International Journal of Developmental Neuroscience; 2020.
Amorosi CA, Myskóva H, Monti MR, Argaraña CE, Morita M, Kemp S, et al. X-Linked Adrenoleukodystrophy: Molecular and Functional Analysis of the ABCD1 Gene in Argentinean Patients. Lee H-C, editor. PLoS One. 2012;7(12):e52635.
Contreras MA, Singh I. Adrenoleukodystrophy: Molecular, metabolic, pathologic, and therapeutic aspects. Handbook of Neurochemistry and Molecular Neurobiology. 2009;13–42.
Powers JM, Deciero DP, Cox C, Richfield EK, Ito M, Moser AB, et al. The dorsal root ganglia in adrenomyeloneuropathy: Neuronal atrophy and abnormal mitochondria. Journal of Neuropathology & Experimental Neurology. 2001;60(5):493–501.
Powers JM, DeCiero DP, Ito M, Moser AB, Moser HW. Adrenomyeloneuropathy. Journal of Neuropathology & Experimental Neurology. 2000;59(2):89–102.
Petroni A, Cappa M, Blasevich M, Solinas M, Uziel G. New findings on X-linked Adrenoleukodystrophy: 5alpha-reductase isoform 2 relative gene expression is modified in affected fibroblasts. Neurosci Lett. 2004;367(3):269-272.
DOI:10.1016/j.neulet.2004.05.115
Engelen M, Kemp S, de Visser M, van Geel BM, Wanders RJ, Aubourg P, et al. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up, and management. Orphanet Journal of Rare Diseases. 2012;7(1):51.
Berger J, Wiesinger C, Eichler F. The genetic landscape of X-linked adrenoleukodystrophy: Inheritance, mutations, modifier genes, and diagnosis. The Application of Clinical Genetics [Internet]. 2015;109.
Laan L, Bredius R, de Coo I, Bakker D, Egeler R. Childhood-onset cerebral X-linked adrenoleukodystrophy. The Lancet. 2000;356(9241):1608–9.
Johns Hopkins Medicine, Ali Fatemi MD. Adrenoleukodystrophy: Inheritance, symptoms. Adrenomyeloneuropathy: diagnosis, treatment
Available:https://www.hopkinsmedicine.org/health/conditions-and-diseases/adrenoleukodystrophy
A publication of the neurological society of India.
[Cited 2022 Jul 28].
Available:https://www.neurologyindia.com/viewimage.asp?img=ni_2019_67_6_1559_273651_f1.jpg
Santiago Palau-Hernandez, Ildefonso Rodriguez-Leyva, Juan Manuel Shiguetomi-Medina Late-onset adrenoleukodystrophy: A review related clinical case report. eNeurologicalSci [Internet]. 2019;14:62–7
[Cited 2021 May 9].
Available:https://www.sciencedirect.com/science/article/pii/S2405650219300073.
Michigan State University. Adrenoleukodystrophy: Prevalence, natural history, disease presentation, effect on fertility and fertility preservation.
Available:https://oncofertility.msu.edu/resources/adrenoleukodystrophy
Eichler F, Mahmood A, Loes D, et al. Magnetic resonance imaging detection of lesion progression in adult patients with X-linked adrenoleukodystrophy. Arch Neurol. 2007;64(5):659-664.
DOI: 10.1001/archneur.64.5.659
Raymond GV, Moser AB, Fatemi A. Table 1. [Plasma Very Long Chain Fatty Acid (VLCFA) Values in X-ALD]. [Internet]. www.ncbi.nlm.nih.gov; 2018.
Available:https://www.ncbi.nlm.nih.gov/books/NBK1315/table/x-ald.T.plasma_very_long_chain_fatty_aci/
Hugo W Moser, Ann B Moser, Steven J Steinberg, Stephan Kemp. Diagnosis of ALD [Internet]. Adrenoleukodystrophy.info; 2017.
Available:https://adrenoleukodystrophy.info/clinical-diagnosis/diagnosis-of-ald
Martin JJ, Ceuterick C, Martin L, Libert J. Skin and conjunctival biopsies in adrenoleukodystrophy. Acta Neuropathol. 1977;38(3):247-250.
DOI:10.1007/
Ferrer I, Aubourg P, Pujol A. General aspects and neuropathology of x-linked adrenoleukodystrophy. Brain Pathology. 2009;20(4):817–30.
Bray S, Krongold M, Cooper C, Lebel C. Synergistic effects of age on patterns of white and gray matter volume across childhood and adolescence. ENEURO. 2015;2(4):ENEURO.0003-15.2015.
Weerakkody Y. X-linked adreno- leukodystrophy. Radiology Reference Article Radiopaedia.org [Internet]. Radiopaedia; 2022.
[Cited 2022 Jul 28].
Available:https://radiopaedia.org/articles/x-linked-adrenoleukodystrophy-1?lang=us
Liberato AP, Mallack EJ, Aziz-Bose R, et al. MRI brain lesions in asymptomatic boys with X-linked adrenoleukodystrophy. Neurology. 2019;92(15):e1698-e1708.
DOI:10.1212/WNL.0000000000007294
Previously Nominated Conditions [Internet]. The official website of the U.S. Health Resources & Services Administration; 2017.
Available:https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp/previous-nominations.html